CORI acquired by private-equity firm for $12.50/sh—a 50% premium to today’s 4pm close: https://finance.yahoo.com/news/corium-announces-agreement-gurnet-point-200300315.html There’s also a $0.50 CVR contingent on FDA approval of Corplex Donepezil, a transdermal formulation of Aricept, for AD. CORI IPOd 4.5 years ago at $8.00/sh (#msg-100011927), so the compound annual return from IPO to buyout was approximately 9%. p.s. Chris Viehbacher, ex-CEO of SNY, is the managing partner of the private-equity firm in this transaction.